



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE MEETING HELD ON WEDNESDAY 15th NOVEMBER 2017
AT 12.30pm

IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL

PRESENT:

Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chairperson)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr T McKenzie (TM)	GP, EL CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mrs L Holden (LH)	Pharmacist LCFT (representing Ms S Ramdour)

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2017/152: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr Y Naheed	GP, EL CCG
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD

2017/153: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2017/154: MINUTES OF OCTOBER MEETING:

Accepted as a correct record.

2017/155: MATTERS ARISING:

Not on action sheet:

2017/138: Formulary Updates

Sodium Chloride Nebules – clarified post meeting that the licensed product 7% must be prescribed by brand: Resp-Ease®
Unlicensed products and strengths -

Traffic Light: AMBER.

Traffic Light: RED

From Action Sheet:

2017/137: LMMG Recommendations (from Sept) Melatonin Position Statement – to bring back after further LMMG discussions. Item closed.

2017/137: LMMG Recommendations (from Sept) Vitamin D Position Statement – for January meeting.

2017/142: ELHT Urinary Catheter Policy – reference to Instillagel® has been changed to generic. Item closed.

From previous meeting:

2017/099: ELHT: Venous Thromboembolism (VTE): Diagnosis & Management (Non-Obstetric) – clarification received that follow up actions for thrombophilia screening & cancer will be included in policy and will be secondary care actions.

2017/156: NEW PRODUCT REQUEST – CEFTAZIDIME- AVIBACTAM

Requested by microbiologists for treatment of licensed indications caused by multi-drug resistant organisms. It should only be on advice of microbiologist.

Resolved: Ceftazidime-Avibactam approved for inclusion on formulary on advice of microbiologist only.

Traffic light: RED

2017/157: UNLICENSED PRODUCT REQUEST - TIOPRONIN

Requested by Mr Srirangam, Urologist, for the reduction in stone formation in patients with cystinuria. It is included in European Association of Urology guidance for this condition. Approved for inclusion in formulary on urologist recommendation only.

Resolved: Tiopronin included on formulary on urologist recommendation only.

Traffic light: RED

2017/158: LMMG CONSULTATIONS (for Dec LMMG)

Patiromer Recommendation – it is not clear where this drug would fit into practice. Concern was expressed at the levels of potassium that were being treated, the other medications that the patients were potentially taking and the lack of monitoring. It may be appropriate for a small number of dialysis patients but would need renal opinion. Suggest it should be Red or Black traffic light.

Antihyperglycaemics Guidelines – comments were made that the document was reflective of Nottingham CCG guideline so acknowledgement should be referenced. In general the guideline was supported. Comments from BwD GP to be included in the response. It will need to be cross checked with the ELHE formulary.

Stoma & Continence Prescribing Guideline – LR has sent comments to LMMG from CCG specialist appliance nurse.

Infant Formula Feeds Prescribing Guidance – updated guidance to provide practical prescribing information for prescribers.

Psoriatic Arthritis Pathway – similar to RA pathway. Supported by ELMMB. Rheumatologists will send response direct to LMMG.

FreeStyle Libre® Position Statement – Position statement has been developed by the Regional Medicines Optimisation Committee (RMOC). A number of concerns have been flagged in relation to the statement which have been fed back to LMMG by the CCG. DSNs have also reported some safety concerns re. accuracy. Paediatricians have produced a lengthy response in favour of use for children and this will be sent to LMMG. ELMMB suggest it should be red with restricted use.

Resolved: CW to send comments to LMMG

2017/159 LMMG RECOMMENDATIONS (from Oct LMMG)

Trimbow® Recommendation

LMMG recommendation accepted as written for ELHE. **Traffic Light: GREEN**

Secukinumab for treatment of Palmoplantar Psoriasis

LMMG recommendation accepted as written for ELHE. **Traffic Light: RED**

Gastroenterology Biologics Pathway - updated

LMMG pathway accepted for ELHE.

2017/160: FORMULARY UPDATES

Somatropin – currently included on as amber. It was agreed to adopt the GMMMG shared care documents to support use locally.

Resolved: Formulary to be updated as above

2017/161: ELMMB TERMS OF REFERENCE UPDATE

The terms of reference to be updated to include that in ELHT the minutes are forwarded to the Clinical Effectiveness Committee and to the Sustainability Board for the CCG's. The Antimicrobial Stewardship group to be included as group to send their minutes to ELMMB.

Resolved: Terms of reference to be amended and included in overarching policy.

2017/162: NICE RECOMMENDATIONS (from Oct)

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee [TA477] is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma [TA478] is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Reslizumab for treating severe eosinophilic asthma (TAG 479) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Tofacitinib for moderate to severe rheumatoid arthritis [TA480] is recommended as an option by NICE. Approved in line with NICE.
CCG Commissioned (Blueteq form required) **Traffic Light: RED**

Immunosuppressive therapy for kidney transplant in adults (TAG 481) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

Immunosuppressive therapy for kidney transplant in children and young people (TAG 482) is recommended as an option by NICE. Approved in line with NICE.
NHS England Commissioned **Traffic Light: RED**

STANDING ITEMS

2017/163: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – Oct 2017

Minutes acknowledged

2017/164: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Aug 2017

Minutes acknowledged

DATE OF NEXT MEETING – The meeting planned for 20th December has been cancelled.

Next meeting is **Wednesday 17th January 2018 12.30pm**, Seminar Room 6, Learning and Development Centre, RBH.

Meetings for 2018 are on 3rd Wednesday of each month in Learning Centre, RBH

17 th January	Seminar Room 6
21 st February	Seminar Room 6
21 st March	Room TBC
18 th April	Room TBC
16 th May	Room TBC
20 th June	Room TBC
18 th July	Room TBC
15 th August	Room TBC
19 th September	Room TBC
17 th October	Room TBC
21 st November	Room TBC
19 th December	Room TBC

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 15th NOVEMBER 2017

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2017/137	LMMG Recommendations (from Sept) Vitamin D Position Statement – to be considered together with ELHE guidelines & products used	JV	Jan 18
2017/161	ELMMB Terms Of Reference Update – Amend terms of reference and include in overarching policy	LR	Jan 18